Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Bionik Laboratories Corp. (BNKL)
|
Add to portfolio |
|
|
|
| Price: |
$0.80
| | Metrics |
| OS: |
6.88
|
M
| |
|
|
| Market cap: |
$5.5
|
M
| |
-610
|
% ROIC
|
|
Net debt:
|
$916.1
|
k
| |
|
|
|
EV:
|
$6.42
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($4.9)
|
M
| |
|
|
|
EBIT
|
($4.9)
|
M
| |
|
|
| EPS |
($0.81)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Mar-31-22 | Mar-31-21 | Mar-31-20 | Mar-31-19 | Mar-31-18 | Mar-31-17 | Mar-31-16 | Dec-31-15 |
| Revenues | 1.3 | 1.2 | 2.2 | 3.2 | 1.0 | 0.6 | 0.0 | 0.0 |
| Revenue growth | 6.7% | -44.6% | -33.7% | 228.7% | 72.6% | -1456.2% | -9.0% | -223.4% |
| Cost of goods sold | 0.3 | 0.3 | 0.9 | 1.6 | 0.4 | 0.4 | 0.0 | -11.8 |
| Gross profit | 1.0 | 0.9 | 1.3 | 1.6 | 0.6 | 0.2 | 0.0 | 11.8 |
| Gross margin | 74.8% | 77.4% | 58.5% | 49.8% | 59.2% | 32.0% | 100.0% | -34778.8% |
| Selling, general and administrative | | | | | | | | |
| Sales and marketing | 1.9 | 1.0 | 2.2 | 2.3 | 2.0 | 1.2 | | |
| Research and development | 1.0 | 1.5 | 3.9 | 3.2 | 2.8 | 2.7 | 1.4 | 1.5 |
| General and administrative | 2.8 | 4.5 | 4.6 | 3.9 | 3.6 | 3.3 | 3.7 | 2.7 |
| EBITA | -3.2 | -4.6 | -9.7 | -8.2 | -17.7 | -8.0 | -14.3 | -6.2 |
| EBITA margin | -250.4% | -388.0% | -452.0% | -251.2% | -1788.6% | -1403.0% | 33812.9% | 18313.5% |
| Amortization of intangibles | 1.6 | 1.5 | 1.4 | 0.3 | 0.3 | 0.6 | | |
| EBIT | -4.8 | -6.2 | -11.2 | -8.4 | -18.0 | -8.6 | -14.3 | -6.2 |
| EBIT margin | -374.7% | -515.8% | -518.5% | -259.8% | -1821.4% | -1499.2% | 33812.9% | 18313.5% |
| Pre-tax income | -10.4 | -13.6 | -25.0 | -10.6 | -14.6 | -8.1 | 1.0 | -5.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -10.4 | -13.6 | -25.0 | -10.6 | -14.6 | -8.1 | 0.0 | -5.6 |
| Net margin | -817.1% | -1141.3% | -1161.7% | -325.2% | -1481.2% | -1410.9% | 0.0% | 16465.3% |
| |
| Diluted EPS | ($1.78) | ($2.66) | ($5.61) | ($4.47) | ($21.73) | ($0.09) | $0.00 | ($0.08) |
| Shares outstanding (diluted) | 5.8 | 5.1 | 4.5 | 2.4 | 0.7 | 91.8 | 80.0 | 67.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|